OpenEvidence
openevidence.com
AI clinical evidence search engine that helps physicians find answers from medical literature.
Quick Information
- Category:
- Research & Search
- Pricing:
- Free
- Platforms:
- Web, iOS, Android
- Free Plan:
- Yes
- Last Verified:
- September 2026
What Is OpenEvidence?
OpenEvidence is an AI medical research and clinical decision support platform, free for verified healthcare professionals in the US, running on an ad-supported model where revenue comes primarily from pharmaceutical and medical device advertising shown during the brief loading period while answers generate. Access requires a US NPI (National Provider Identifier) number, and the company withdrew from the EU and UK in April 2026.
Its business scale and momentum have grown genuinely substantial: in January 2026, the Miami-based company closed a $250 million Series D led by Thrive Capital and DST Global, doubling its valuation to $12 billion, with clinical consultation volume reaching approximately 20 million/month and annual revenue reaching $100 million by that same month — reflecting real adoption among US healthcare professionals for the free, ad-supported model.
It's aimed at verified US healthcare professionals wanting free AI-powered medical research and clinical decision support, with the April 2026 withdrawal from the EU and UK meaning international clinicians outside the US no longer have access — the free-to-use, ad-supported model remains specifically limited to US NPI holders. See our Research tools directory for related medical research tools.
What Can You Use OpenEvidence For?
AI medical research
Provides AI-powered research support for clinical questions.
Clinical decision support
Supports clinical decision-making with AI-generated, evidence-based answers.
Free healthcare professional access
Provides free access to verified US healthcare professionals with an NPI number.
OpenEvidence Features
- AI clinical research — Answers clinical research questions using AI, grounded in medical evidence.
- Ad-supported free access — Provides completely free access funded by pharmaceutical and medical device advertising.
- NPI-verified access — Requires a verified US National Provider Identifier number for access.
Who Is OpenEvidence For?
- US healthcare professionals — Uses free, NPI-verified access to AI-powered medical research and clinical support.
- Clinicians needing quick evidence-based answers — Gets clinical decision support without any subscription cost.
OpenEvidence Pros & Limitations
What We Like
- Genuinely free for verified US healthcare professionals, funded entirely by advertising
- Massive real-world adoption — approximately 20 million clinical consultations/month as of January 2026
- Substantial recent funding ($250M Series D, $12B valuation) suggests continued platform investment
Limitations
- Access requires a US NPI number, excluding non-US healthcare professionals
- Withdrew from the EU and UK entirely in April 2026, cutting off previous international access
- Ad-supported model means pharmaceutical advertising is shown during use
OpenEvidence Pricing
Free
Pricing was last verified September 2026. Check the official website for the latest pricing.
AI Listing Jungle Ranking
- Global Rank:
- #590
- Overall Score:
- 27.1/100
- Monthly Users:
- –
- Rank Change:
- ▲ 14
This ranking reflects AI Listing Jungle's own independent scoring methodology and is not an endorsement by OpenEvidence or its company. How Our Rankings Work
Frequently Asked Questions
Is OpenEvidence free?
Yes, completely free for verified healthcare professionals with a US NPI number, funded by advertising.
Is OpenEvidence available in Europe?
No, the company withdrew from the EU and UK in April 2026.
How does OpenEvidence make money?
Through pharmaceutical and medical device advertising shown during the answer-loading period.
How much has OpenEvidence raised?
A $250 million Series D in January 2026, doubling its valuation to $12 billion.
Our Take
OpenEvidence's genuinely free, ad-supported model for verified US healthcare professionals has driven substantial real adoption, with roughly 20 million monthly consultations as of January 2026.
International clinicians should note the April 2026 EU/UK withdrawal — access now remains specifically limited to US NPI holders.
OpenEvidence Alternatives
OpenEvidence Comparisons
Ready to try OpenEvidence?
Visit the official website to get started.
Visit Official WebsiteAI Listing Jungle is an independent AI tools directory. Product names, logos, and trademarks belong to their respective owners.